Actinogen Medical’s Promising Advances in Neurological Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2024
0mins
Source: Business Insider
Company Update: Actinogen Medical Limited successfully passed all resolutions at its Annual General Meeting, including a special resolution to increase placement capacity.
Drug Development: The company is advancing its drug Xanamem for treating Alzheimer’s and depression, with positive trial results that have attracted investor interest in its ongoing neurological treatment trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
